bioAffinity Technologies Reports Q3 2026 Revenue of About $1.1 Million
The company reported a net loss of $5.3 million. Year-to-date testing revenue rose 79% to about $1.1 million, and CyPath Lung test sales doubled versus the first nine months of 2025.
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million and a net loss of $5.3 million. CyPath Lung test sales doubled year to date compared with the first nine months of 2025, while testing revenue rose 79% to approximately $1.1 million. The company ended Septemb…